In summary, for the first time, we revealed that PERK was activated in glioma and PERK silencing reduced glioma cell viability under low glucose stress in culture and suppressed glioma growth in vivo via inhibition of p-AKT and glioma cell glycolysis. The gene discussed is AKT1; the disease is central nervous system cancer.